Clinical data | |
---|---|
Trade names | Bromfed, Dimetapp, Bromfenex, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682545 |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | Liver |
Elimination half-life | 24.9 ± 9.3 hours[1] |
Excretion | Kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.001.507 |
Chemical and physical data | |
Formula | C16H19BrN2 |
Molar mass | 319.246 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Brompheniramine, sold under the brand name Dimetapp among others, is a first-generation antihistamine drug of the propylamine (alkylamine) class.[2] It is indicated for the treatment of the symptoms of the common cold and allergic rhinitis, such as runny nose, itchy eyes, watery eyes, and sneezing. Like the other first-generation drugs of its class, it is considered a sedating antihistamine.[2]
It was patented in 1948 and came into medical use in 1955.[3] In 2021, the combination with dextromethorphan and pseudoephedrine was the 294th most commonly prescribed medication in the United States with more than 500,000 prescriptions.[4][5]